People: Introducing our first PhD Student – Michael Papanicoloau

Thomas R. Cox, Sep 2018

Michael Papanicoloau - Matrix and MetastasisThe lab is excited to be welcoming our first Ph.D. student Michael Papanicoloau who has just started in the lab. Michael joins us after completing his Honours degree in Biomedical Science at UTS and the Woolcock Institute of Medical Research.

Having been awarded a prestigious UTS Research Excellence Scholarship, Michael’s Ph.D. will focus on understanding how the extracellular matrix changes over time in solid tumours, in particular breast cancer, and how these changes feed into the pathological progression of the disease at both primary and secondary sites.

 

Publication: Removing physiological motion from intravital and clinical functional imaging data

Thomas R. Cox, Jul 2018

Removing physiological motion from intravital and clinical functional imaging data

Galene is a new tool just published in eLife that can correct for physiological motion in live imaging data post-acquisition.

Galene Motion Correction Software

eLife digest

Understanding how molecules and cells behave in living animals can give researchers key insights into what goes wrong in diseases such as cancer, and how well potential treatments for these diseases work. Continue reading

Publication: Charting the unexplored extracellular matrix in cancer

Thomas R. Cox, Apr 2018

Charting the unexplored extracellular matrix in cancer

Our new review on the recent advances in mapping the extracellular matrix in cancer has just been published in the International Journal of Experimental Pathology.

Composed of hundreds of different building blocks, the extracellular matrix (ECM) makes up the complex, highly cross‐linked, three‐dimensional (3D) network of macromolecules (proteins, glycoproteins and its subgroup of proteoglycans, polysaccharides (glycosaminoglycans), elastins and carbohydrates) that surround cells. It is essential to correct organisation and function of all tissues and organs, yet we know remarkably little about the assembly and organisation of these supramolecular structures of the ECM. In this review we discuss some of the recent advances and technologies that are helping us delve deeper into the matrix and further our understanding of the impact that dysregulated ECM has in diseases such as cancer.

IJEP Charting the unexplored extracellular matrix in cancer

Extracellular matrix building blocks

Continue reading

Publication: Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease

Thomas R. Cox, Jan 2018

Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease

Our new review on the how hypoxia is important in cancer-associated bone disease has just been published in Calcified Tissue International.

Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease

What is Hypoxia and why is it important in cancer?

Continue reading

Publication: Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology

Thomas R. Cox, Dec 2017

Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology

Our new paper on alternative collagen sources for 3D organotypic cultures for use as pre-clinical models is now out in Scientific Reports

Collaroo: 3D Organotypic matrices for cancer biology

Cellular interactions with the extracellular matrix (ECM) occur in a three-dimensional (3D) context and this essential aspect of the tumour microenvironment can lead to altered sensitivity to therapeutics and even act as a barrier to their delivery. This key feature is often overlooked in pre-clinical studies and is likely one of the central factors contributing to the high attrition rates of lead compounds within the pharmaceutical industry. This organotypic platform allows assessment of lead compounds in both the stromal compartment or in a 3D co-culture setting using large scale collagen preparations from alternative sources.

Continue reading

People: Jessica joins M&M

Thomas R. Cox, Dec 2017

Jessica Chitty (Matrix and Metastasis Lab)I’m delighted to announce that Jessica Chitty will shortly be joining the lab as a postdoctoral research fellow. Jessica has just completed her Ph.D at the University of Queensland and is making the move south to join our team.

Having completed a degree in Biochemistry in the UK, and her Ph.D in Australia, Jessica brings experience in investigating the translational repurposing of key anti-cancer/antimycotic targets, along with significant expertise in enzyme biochemistry and molecular biology in the context of rational drug design, focusing towards translational research.

Jessica will focus her work on our ongoing interest into the lysyl oxidase family of enzymes and their role in pancreatic cancer.

Funding: Susan G. Komen® Career Catalyst Research Grant

Susan G Komen logoThomas R. Cox, Sep 2017

We’re delighted to announce the we have been awarded a research grant from the Susan G. Komen Foundation, the world’s leading breast cancer organisation.

The grant will support a project investigating how stiffness in breast tissue can drive the aggressive behaviour of cancer cells, and how tissue stiffness impacts on the effectiveness of breast cancer treatments

Continue reading

PostDoc position available to start late 2017

Thomas R. Cox, Aug 2017

Matrix and Metastasis Lab Hiring

We are seeking a full-time dedicated PostDoc to work in the Cancer Division Matrix & Metastasis Group headed by Dr. Thomas Cox.  The group combines the use of 3D models of cancer with novel state-of-the-art imaging approaches to reveal how the extracellular matrix drives cancer progression and metastasis. Our mission is to establish targeting of the extracellular matrix as a viable therapeutic approach in the treatment of solid cancers.

Continue reading